Elective neck dissection improves the survival of patients with T2N0M0 oral squamous cell carcinoma: a study of the SEER database

Alimujiang Wushou1,2, Feiluore Yibulayin3, Lu Sheng1,2, Yuan Luo1,2 and Zhi‑cheng Yang1,2*

Abstract

Background: Treatment of clinical N0 neck tumours is controversial in early‑stage oral squamous cell carcinoma (OSCC), possibly because T1N0M0 and T2N0M0 merge together at early stages. The purposes of this study were to compare survival outcomes only for T2N0M0 cases based upon treatment elective neck dissection versus neck observation.

Methods: T2N0M0 OSCC cases were identified in the Surveillance, Epidemiology, and End Results database of the United States National Cancer Institute between 2004 and 2015. Survival curves for different variable values were generated using Kaplan‑Meier estimates and compared using the log‑rank test. Variables that achieved significance at \( P < 0.05 \) were entered into multivariable analyses via the Cox proportional hazards multivariate regression.

Results: A total of 2857 patients were selected, and 2313 cases were available for disease specific survival (DSS). The 5‑year and 10‑year overall survival (OS) were 66.7 and 46% for patients receiving elective neck dissection (END), respectively, and 56.4 and 37.2% for patients with neck observation (\( P < 0.0001 \)). The 5‑year and 10‑year DSS were 73.6 and 64% for the END group, respectively, versus 64.5 and 54.5% for the neck observation group (\( P < 0.0001 \)). More importantly, performing END was independently associated with favourable DSS and OS for patients with T2N0M0 OSCC [hazard ratio (HR) = 0.769, \( P = 0.0069 \) for DSS; HR = 0.829, \( P = 0.0031 \) for OS, neck observation group as reference] according to multivariate survival analysis.

Conclusion: END is recommended for T2N0M0 OSCC cases and it is associated with improved DSS and OS.

Keywords: Oral squamous cell carcinoma, T2N0M0, Elective neck dissection, Surgical treatment, SEER database

Background

Head and neck squamous cell carcinoma is increasingly prevalent worldwide and is the 16th leading cause of cancer death. Oral squamous cell carcinoma (OSCC) is the most common cancer of the oral cavity, representing more than 95% of all cases and making up almost half of newly diagnosed head and neck squamous cell carcinoma [1, 2]. Overall survival (OS) rates of OSCC varied from 10 to 82% depending on various prognostic factors, including age, race, sex, primary site, drinking, smoking, human papillomavirus status, American Joint Committee on Cancer (AJCC) stage, pathological differentiation and treatment modalities [3]. Among these prognostic factors distant metastasis is one of the strongest indicators. Another important
prognostic factor in survival is the presence of lymph node metastasis. It has been reported that cervical lymph node metastasis and extranodal extension are prerequisites for distant metastasis development [4].

The existence of cervical lymph node metastasis demonstrates the most important clinico-pathological prognostic factor. The presence of even one positive cervical lymph node is associated with a 50% reduction in OS [5]. Thus, appropriate treatment of the cervical lymph node is as important as treating the primary site to achieve good oncologic results. The optimal treatment protocol for patients with early stage (T1–2N0M0) tumours has been debated in the past several decades; no consensus has been reached because of similar prognosis between elective neck dissection (END) and neck observation. Head and neck surgical oncologists prefer preventive END to avoid regional recurrence; supraomohyoid neck dissection is well established [6]. However, others believe END is an aggressive regime, especially for young female patients with T1N0M0 tumours, mostly because of the neck contour changes and some surgical complications. Therefore, a wait-and-watch policy is recommended, which favours regular consultation without simultaneous neck dissection [7].

The AJCC T stage is an independent prognostic indicator, and T2-stage OSCC has demonstrated worse prognosis than T1 [8]. However, most previous studies have merged T1 and T2 in early stages of evaluating prognosis [9]. When clinically dealing with T1- and T2-stage OSCC, surgeons have encountered challenging treatment strategies. Surgically treated T1-stage OSCC typically does not require defect repair or postoperative defects can be closed with adjacent flaps. However, the postoperative defect of T2-stage tumours often requires free flap repair and simultaneous END facilitated oral defect reconstruction, which would improve the patient quality of life [10]. Therefore, when assessing prognosis, T1N0M0 and T2N0M0 stage tumours should be separately evaluated instead of together [11]. In view of organ preservation or surgical reconstruction, we believe that surgical treatment is better than radiotherapy, chemotherapy or their combination for T2N0M0 OSCC patients. Furthermore, simultaneously performing END can prevent regional recurrence and is helpful for performing free flap reconstruction. Lastly, postoperative defect repair and functional restoration will eventually improve overall survival. Here, in order verify our above postulated conditions, we present a retrospective investigation comparing survival outcomes only for T2N0M0 cases based upon treatment END versus neck observation.

**Methods**

**Study cohort**

The study population was extracted from the Surveillance, Epidemiology, and End Results (SEER) database of the United States National Cancer Institute using its software (https://seer.cancer.gov, SEER*Stat 8.3.6). Patients were identified via the International Classification of Diseases for Oncology, Third Edition (ICD-O-3) as previously described [12]. Briefly, the OSCC cases were selected through the ICD-O-3 morphologic and topographic codes: 8050–8076, 8078, 8083, 8084, 8094, C01.9, C02.0, C02.1, C02.2, C02.8, C02.9, C03.0, C03.1, C03.9, C04.0, C04.9, C05.0, C06.0, C06.1 and C06.2.

We selected only pathologically confirmed T2N0M0 (AJCC stage II) OSCC primary cases. Patients receiving neck dissection were identified through the SEER fields for regional lymph node surgery. The variables in the analysis included tumour origination, marital status at diagnosis, age at diagnosis, sex, race, pathological differentiation, whether neck dissection was performed, treatment modalities, vital status and follow-up period. Our study used the established data and did not involve interactions with human subjects. Therefore, institutional review board approval was not required.

**Statistical analysis**

Differences in numerical variables were evaluated with Student’s test or the non-parametric Wilcoxon test. Categorical variables were compared by the chi square test or Fisher exact test. Survival analysis were performed using the Kaplan-Meier estimates. Independent prognostic factors were identified via the Cox proportional hazards multivariate regression. Data analysis were carried out applying Statistical Package for Social Sciences, Version 23.0, for Windows (SPSS, Chicago, IL) and statistical packages R (The R foundation; http://www.r-project.org; version 3.4.3), Empower R (http://www.empowerstats.com, Boston, MA).

**Results**

**Clinicopathologic characteristics**

A total of 2857 patients were selected. The cohort consisted of 1691 males and 1166 females with a mean age of 64 years. Caucasian accounted for 84.6% (2418/2857) and black American 6% (172/2857) of the study population. The overall mean follow-up period was 54.2 months (range, 0–155 months). In more than half of the cases (1611/2857, 56.4%), the orientation was tongue. END for regional lymph node surgery. The variables in the analysis included tumour origination, marital status at diagnosis, age at diagnosis, sex, race, pathological differentiation, whether neck dissection was performed, treatment modalities, vital status and follow-up period. Our study used the established data and did not involve interactions with human subjects. Therefore, institutional review board approval was not required.

For disease specific survival (DSS) analysis, 2313 cases were available, including 939 females and 1374 males.
| Parameters                        | Overall survival | Disease specific survival |
|----------------------------------|-------------------|--------------------------|
|                                  | Neck observation  | Neck dissection          | Neck observation  | Neck dissection          |
|                                  | Alive  | Dead  | P-value | Alive  | Dead  | P-value | Alive  | Dead  | P-value |
| Tumor origination                | Floor of mouth   | 63     | 75      | 0.396  | 176    | 130     | 0.000  | 62     | 29     | 0.678   |
|                                  | Gum and Other Mouth | 179   | 179    | 0.000  | 249    | 195     | 0.000  | 177    | 96     | 0.000   |
|                                  | Tongue           | 298    | 275    | 0.000  | 696    | 340     | 0.000  | 291    | 168    | 0.000   |
| Marital status at diagnosis      | Single           | 76     | 83     | 0.000  | 196    | 113     | 0.000  | 76     | 43     | 0.000   |
|                                  | Married          | 330    | 220    | 0.000  | 646    | 336     | 0.000  | 323    | 136    | 0.000   |
|                                  | Other status     | 111    | 198    | 0.000  | 217    | 192     | 0.000  | 108    | 99     | 0.000   |
| Age period                       | 20–29            | 2      | 2      | 0.000  | 17     | 4       | 0.000  | 2      | 2      | 0.000   |
|                                  | 30–39            | 18     | 3      | 0.000  | 65     | 15      | 0.000  | 18     | 2      | 0.000   |
|                                  | 40–49            | 54     | 28     | 0.000  | 179    | 58      | 0.000  | 53     | 23     | 0.000   |
|                                  | 50–59            | 137    | 72     | 0.000  | 325    | 137     | 0.000  | 137    | 49     | 0.000   |
|                                  | 60–69            | 139    | 119    | 0.000  | 296    | 194     | 0.000  | 138    | 64     | 0.000   |
|                                  | 70–79            | 110    | 136    | 0.000  | 182    | 163     | 0.000  | 105    | 77     | 0.000   |
|                                  | 80+              | 80     | 169    | 0.000  | 57     | 94      | 0.000  | 77     | 76     | 0.000   |
| Age at diagnosis                 | Age ≤ 64         | 294    | 159    | 0.000  | 763    | 306     | 0.000  | 292    | 102    | 0.000   |
|                                  | Age > 64         | 246    | 370    | 0.000  | 358    | 359     | 0.000  | 238    | 191    | 0.000   |
| Gender                           | Female           | 249    | 237    | 0.067  | 427    | 251     | 0.084  | 242    | 137    | 0.265   |
|                                  | Male             | 291    | 292    | 0.000  | 694    | 414     | 0.000  | 288    | 156    | 0.000   |
| Race                             | White            | 464    | 462    | 0.053  | 920    | 570     | 0.100  | 454    | 251    | 0.786   |
|                                  | Black            | 25     | 29     | 0.000  | 76     | 42      | 0.000  | 25     | 17     | 0.000   |
|                                  | Others           | 46     | 37     | 0.000  | 119    | 51      | 0.000  | 46     | 24     | 0.000   |
| Pathological grade               | Grade I          | 177    | 133    | 0.006  | 242    | 122     | 0.013  | 175    | 55     | 0.000   |
|                                  | Grade II         | 236    | 263    | 0.000  | 683    | 398     | 0.000  | 232    | 154    | 0.000   |
|                                  | Grade III + IV   | 73     | 93     | 0.000  | 161    | 129     | 0.000  | 71     | 66     | 0.000   |
| Radiotherapy                     | No               | 345    | 324    | 0.372  | 694    | 378     | 0.035  | 339    | 159    | 0.006   |
|                                  | Yes              | 195    | 205    | 0.000  | 427    | 287     | 0.000  | 191    | 134    | 0.000   |
| Chemotherapy                     | No               | 478    | 471    | 0.789  | 1034   | 599     | 0.076  | 469    | 250    | 0.022   |
|                                  | Yes              | 62     | 58     | 0.000  | 84     | 66      | 0.000  | 61     | 43     | 0.000   |
| Treatment                        | Surgery          | 345    | 323    | 0.478  | 694    | 378     | 0.075  | 339    | 158    | 0.022   |
|                                  | Surgery + RT     | 133    | 147    | 0.000  | 340    | 221     | 0.000  | 130    | 91     | 0.000   |
|                                  | Surgery + RT + chemotherapy | 62 | 57 | 0.789 | 87 | 66 | 0.076 | 61 | 43 | 0.000 |
The mean follow-up period for DSS was nearly the same as OS. END was performed in 1488 cases in this cohort. Summary statistics of DSS status are presented in Table 1. When stratified by histologic grade, 528 cases were of grade I, 1289 cases of grade II, and the remaining 384 cases were of grades III and IV. Histologic grade information was missing for 111 cases. According to the distribution of sample sites, we divided the study population into three groups: (A) floor of mouth, (B) tongue and (C) other sites combined, including upper gum, lower gum, hard palate, cheek mucosa, vestibule of mouth and retromolar area.

**Survival analysis**

Kaplan-Meier analysis was applied for time-to-event analysis. Regardless of all other factors, the 5-year and 10-year OS were 66.7 and 46%, respectively, for patients receiving END and 56.4 and 37.2% for patients with neck observation ($P < 0.0001$, Fig. 1). Significant OS differences were found depending on age range ($P < 0.0001$), mean age ($P < 0.0001$), marital status at diagnosis ($P < 0.0001$), pathological grade ($P < 0.0001$), tumour orientation ($P = 0.015$), pathological grade ($P < 0.0001$), radiotherapy ($P < 0.0001$), chemotherapy ($P = 0.0021$) and different treatment modalities ($P < 0.0001$) (Fig. 1).

In the survival analysis for DSS, patients treated with END showed significantly higher survival rates than patients in the neck observation group ($P < 0.0001$). The 5-year and 10-year DSS for all causes combined were 73.6 and 64% for the END group, respectively, versus 64.5 and 54.5% for the neck observation group. Additionally, remarkable survival differences were identified depending on age range ($P < 0.0001$), mean age ($P < 0.0001$), marital status at diagnosis ($P < 0.0001$), tumour orientation ($P = 0.015$), pathological grade ($P < 0.0001$), radiotherapy ($P < 0.0001$), chemotherapy ($P = 0.0021$) and different treatment modalities ($P < 0.0001$) (Fig. 2).

**Cox regression multivariate analysis**

To determine the efficacy of END based on various clinicopathological factors, all significant factors in the
survival analysis were entered into the multivariable analysis based on the Cox regression model.

The END was favourably associated with better DSS and OS [hazard ratio (HR) 95% confidence interval (CI) = 0.769 (0.675–0.939), \( P = 0.0069 \) for DSS; HR (95% CI) = 0.829 (0.732–0.939), \( P = 0.0031 \) for OS, neck observation as reference].

Fig. 2 Disease specific survival curves of cases with T2N0M0 OSCC compared according to (A) age range, (B) mean age at diagnosis, (C) marital status at diagnosis, (D) tumor orientation, (E) pathological differentiation, (F) radiotherapy, (G) neck dissection, (H) chemotherapy and (I) treatment modalities.
The higher pathological grades were adversely associated with DSS and OS [Grade II HR (95% CI) = 1.564 (1.257–1.947), \( P = 0.0001 \); Grade III+IV, HR (95% CI) = 2.193 (1.702–2.826), \( P < 0.0001 \) for DSS; Grade II, HR (95% CI) = 1.311 (1.127–1.525), \( P = 0.0004 \); Grade III+IV, HR (95% CI) = 1.772 (1.47–2.137), \( P < 0.0001 \) for OS, Grade I as reference]. The details of the multivariate Cox regression analysis are presented in Fig. 3.

**Discussion**

Management of the clinical N0 neck tumour is controversial in early OSCC [13]. The metastasis rate of the cervical lymph node is inconsistent according to previous reports. Most importantly, occult metastases exist in early stage OSCC [14]. Previous studies have demonstrated that the occult metastasis rate was approximately 25% in for OSCC patients treated with early-stage END [15–18]. It may be concluded that one in four patients is exposed to the risk of regional recurrence or even developing distant metastasis. However, few studies have clarified whether these patients were T1N0M0 or T2N0M0 and further did not evaluate the effects of performing END on prognosis. This report, to our knowledge, analyses the largest population of T2N0M0 OSCC patients independently to date. We found that performing END effectively improved T2N0M0 OSCC survival and is an independent prognostic indicator.

Based on our results, pathological differentiation is another important prognostic indicator. Compared with grade I well-differentiated OSCC cases, the other three grades (Grades II, III and IV) are adversely associated with DSS and OS. The tumour subtype is an important prognostic factor that has been neglected in previous studies in deciding whether to use END. There are many variants of OSCC, having different biological behaviours and prognosis [19–21]. Almost all SCC variants are registered in the SEER database. To ensure the accuracy of our results, we filtered two variants (8070/3 and 8071/3) and found no significant survival differences between the two variants (\( P > 0.05 \)).

Regarding oral solid neoplasm, surgical resection remains the most effective treatment modality [22].

**Table 1**

| Variables               | Hazard ratio | HR(95% CI)  | P     |
|-------------------------|--------------|-------------|-------|
| Married vs Single       |              | 0.712 (0.571-0.887) | 0.0025 |
| Age: 70-79 vs 20-29     |              | 2.125 (0.856-5.274) | 0.1043 |
| Age: 80+ vs 20-29       |              | 3.522 (1.403-8.841) | 0.0073 |
| Pathologic grade II vs I|              | 1.564 (1.257-1.947) | 0.0001 |
| Pathologic grade III + IV vs I | | 2.193 (1.702-2.826) | <0.0001 |
| Neck dissection: Yes vs No |            | 0.769 (0.675-0.939) | 0.0069 |
| Radiotherapy: Yes vs No  |              | 1.287 (1.082-1.532) | 0.0044 |

**Fig. 3** Forest plots summarizing hazard ratios for (A) DSS and (B) OS
for small T1-stage tumour postoperative defects, OSCC surgical treatment often involves resection and functional reconstruction [4]. Surgery is irreplaceable for T2N0M0 OSCC patients. Radiotherapy, chemotherapy or their combination cannot achieve as good results as surgery in oral function recovery. We also studied cases treated with methods other than surgery and evaluated their prognosis. The results demonstrated that there were significant survival differences among the various treatment modalities. Patients treated with surgery showed better prognosis than those treated with other means alone or combinations. Without a doubt, the adjuvant roles of radiotherapy and chemotherapy should be admitted in the positive margin of pathologically undifferentiated cases.

There are variances in the survival rates of different tumour orientations [4]. Controversy sexist in the management of T2N0M0 OSCC arising from maxillary gingiva, alveolus, and hard palate [23]. The low incidence of cervical metastases has historically been considered a hallmark of this disease, and a “watch-and-wait” strategy is typically used to control neck lymph node metastases [24, 25]. The results of survival analysis according to the OSCC orientation showed that group A (floor of mouth) and B (tongue) demonstrated better DSS and OS prognosis than group C (other sites). Based on this finding, we concluded that T2N0M0 OSCC of maxillary gingiva, alveolus, and hard palate should be considered as equally aggressive as those at other sites. However, this conclusion may require further subgroup confirmation.

A few limitations of the publicly available SEER database and the current investigation should be acknowledged. First, not all cases have complete information, including important variables such as pathological grade, HPV status and detailed chemotherapy. Second, due to the lack of oral defect reconstruction data, the role of free flap construction for life quality improvement could not be well established. Third, the follow-up period was variable (0–155 months). Finally, the retrospective nature of the current study may have introduced bias into the overall analysis.

**Conclusion**

Most previous retrospective or prospective T1/2N0M0 OSCC studies regarding END had small sample sizes. Decisions on whether to proceed with END versus a “wait-and-watch” approach in T1/2N0M0 is controversial for the following reasons. First, the disease has relatively low incidence. Second, early-stage tumours require much longer follow-up durations to identify differences between the two treatment strategies. Finally, and most importantly, radiochemotherapy has shown similar survival rates compared with surgery in early stage OSCC. Despite the limitation of incomplete data and the study itself, the present investigation is the first of its kind using the largest study population from multiple orientations to show that patients with T2N0M0 OSCC benefited from END associating with improved DSS and OS and it was an important independent prognostic factor. Thus, performing END is recommended for patients with T2N0M0 OSCC cases.

**Abbreviations**

OSCC: Squamous cell carcinoma; OS: Overall survival; AJCC: American Joint Committee on Cancer; END: Elective neck dissection; SEER: Surveillance, Epidemiology, and End Results; ICD-O-3: International Classification of Diseases for Oncology, Third Edition; SPSS: Statistical Package for Social Sciences; DSS: Disease specific survival; HR: Hazard ratio; CI: Confidence interval.

**Acknowledgments**

We acknowledge American Journal Experts (https://www.aje.com, AJE, Durham, NC, USA) for reviewing the manuscript for grammar consistency (ID: L8LJK8I).

**Authors’ contributions**

FY, ZY and AW contributed to the conception and design of the study; FY, LS and YL performed the experiments, FY, LS and AW collected and analyzed data; FY and LS wrote the manuscript; The authors reviewed and approved the final version of the manuscript.

**Availability of data and materials**

Study data was publicly available in the SEER database (https://seer.cancer.gov).

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interest.

**Author details**

1. Department of Oral & Maxillofacial Surgery, Shanghai Key Laboratory of Craniofacial Development and Diseases, Shanghai Stomatological Hospital, Fudan University, 356 Beijing East Road, Shanghai 200001, PR China.
2. Shanghai Key Laboratory of Craniofacial Development and Diseases, Fudan University, 356 Beijing East Road, Shanghai 200001, PR China. 3. Department of Preventive Medicine, School of Public Health, Shanghai Medical College, Fudan University, Shanghai, China.

**Received: 3 December 2020   Accepted: 24 November 2021**

**Published online: 07 December 2021**

**References**

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85.
2. Chaturvedi AK, Anderson WF, Loriot-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31(36):4550–9.
